Global pharma major Lupin Limited has appointed Abdelaziz Toumi as chief executive officer of its newly formed subsidiary, Lupin Manufacturing Solutions (LMS). LMS is engaged in the development, manufacture and sale of active pharmaceutical ingredients (APIs) and is starting to build its contract development and manufacturing operations (CDMO) business.

Toumi is a seasoned leader with a blend of scientific and commercial skills and brings over two decades of experience in the biotech, pharma and CDMO sectors, spanning Europe, North America and Asia. He has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma, where he was responsible for driving growth, innovation and operational excellence. Toumi will be based in Switzerland and will spend considerable time in India.

Toumi holds a Doctorate in Chemical Engineering and a Master’s degree in Business Administration from the University of Southern Queensland.

Commenting on the appointment, Lupin’s managing director, Nilesh Gupta said, “We are delighted to welcome Abdel to our team. He brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers.”